Pfizer Inc. (NYSE:PFE) enjoyed a 13.28% run-up in share price since hitting record low of $38.04. The stock managed 0.98% rise and now stands at $43.09 as of 7/26/2019. At a recent session, the prices were hovering between $42.43 and $43.17. This company shares are 6.17% off its target price of $45.75 and the current market capitalization stands at $242.81B. The recent change has given its price a 0.73% lead over SMA 50 and -7.27% deficit over its 52-week high. The stock witnessed 0.23% gains, 7.81% gains and 6.03% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PFE’s volatility during a week at 1.31% and during a month it has been found around 1.44%.

What Does Pfizer Inc. (PFE) Do?

The company describes itself in regulatory filings as, “Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.” [Text can be found here: under company description.]

Pfizer Inc. (PFE) Top Holders

Institutional investors currently hold around $175.23 billion or 74.8% in PFE stock. Look at its top three institutional owners: Vanguard Group Inc owns $19.39 billion in Pfizer Inc., which represents roughly 7.99% of the company’s market cap and approximately 11.07% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 445,911,789 shares of the stock are valued at $19.21 billion. The third largest holder is State Street Corp, which currently holds $12.82 billion worth of this stock and that ownership represents nearly 5.28% of its market capitalization.

Pfizer Inc. 13F Filings

At the end of March reporting period, 1,018 institutional holders increased their position in Pfizer Inc. (NYSE:PFE) by some 148,393,307 shares, 1,221 decreased positions by 231,379,033 and 252 held positions by 3,687,000,000. That puts total institutional holdings at 4,067,000,000 shares, according to SEC filings. The stock grabbed 118 new institutional investments totaling 19,493,335 shares while 110 institutional investors sold out their entire positions totaling 25,145,750 shares.

Pfizer Inc. (NYSE:PFE) Insider Trades

Multiple company employees have indulged in significant insider trading. Pfizer Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Executive Vice President DAMELIO FRANK A has sold 153,184 shares of Pfizer Inc. (PFE) in the trading session dated Jul. 02, 2019. These shares are worth $6,753,883 and were traded at $44.09 each. The SEC filing shows that MACKENZIE ALEXANDER R performed a sale of 30,000 shares. The Executive Vice President disposed these shares by way of transaction on Jun. 20, 2019. The company’s shares were given away at $44 per share worth to an income of some $1,320,000 to the account of MACKENZIE ALEXANDER R.

Executive Vice President, MACKENZIE ALEXANDER R, sold 15,000 common shares of Pfizer Inc. (PFE) in the open market. In a transaction dated Apr. 01, 2019, the shares were put up for sale at an average price of $42.83, raking in a sum of $642,450. After this sale, 119,430 common shares of PFE are directly owned by the insider, with total stake valued at $5,146,239.

In the transaction dated Mar. 15, 2019, a great number of shares sold came courtesy the Executive Vice President; JOHNSON RADY A disposed a total of 8,700 shares at an average price of $41.13, amounting to approximately $357,831. The insider now directly owns 64,960 shares worth $2,799,126.

Pfizer Inc. (PFE) Analyst Guide

Several analysts have released their opinion on Pfizer Inc. (NYSE:PFE), with 3 analysts believing it is a strong buy. Whereas 5 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 1 strong sell ratings, collectively assigning a 2.36 average brokerage recommendation [T1].